Replies to post #221566 on Biotech Values

[DewDiligence]

DVAX –6% on phase-2 asthma flop:

https://www.sec.gov/Archives/edgar/data/1029142/000156459018030292/dvax-8k_20181129.htm

Dynavax Technologies Corporation…has been informed by its collaborator, AstraZeneca, that initial high-level results from a Phase 2a study indicate AZD1419 treatment was not associated with a statistically significant improvement in the time to loss of asthma control and therefore did not meet the primary endpoint of the study.

No press release.